IPO Listed — 25 Jun 2026
Listing Price: ₹395.20
Avience Biomedicals SME IPO GMP History | Listing Price ₹395.20 & Kostak Rate
Avience Biomedicals SME IPO has been listed on June 25, 2026 at a listing price of ₹395.20, against the issue price of ₹208 — a gain of ₹187.2 (+90%). The GMP peaked at ₹145 on 25 June 2026 and reached a low of ₹63 on 16 June 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Avience Biomedicals SME IPO raised ₹30.24 Cr. through its IPO at a price band of ₹196 to ₹208 per share, with a lot size of 600 shares. The IPO was open for subscription from 18 Jun 2026 to 22 Jun 2026.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 25 Jun 2026 | ₹ 145 | 69.7% | ₹ 0 | ₹ 0 | |
| 24 Jun 2026 | ₹ 130 | 62.5% | ₹ 0 | ₹ 0 | |
| 23 Jun 2026 | ₹ 95 | 45.7% | ₹ 0 | ₹ 0 | |
| 22 Jun 2026 | ₹ 72 | 34.6% | ₹ 0 | ₹ 0 | |
| 21 Jun 2026 | ₹ 70 | 33.7% | ₹ 0 | ₹ 0 | |
| 20 Jun 2026 | ₹ 85 | 40.9% | ₹ 0 | ₹ 0 | |
| 19 Jun 2026 | ₹ 85 | 40.9% | ₹ 0 | ₹ 0 | |
| 18 Jun 2026 | ₹ 85 | 40.9% | ₹ 0 | ₹ 0 | |
| 17 Jun 2026 | ₹ 75 | 36.1% | ₹ 0 | ₹ 0 | |
| 16 Jun 2026 | ₹ 63 | 30.3% | ₹ 0 | ₹ 0 | |
| 15 Jun 2026 | ₹ 70 | 33.7% | ₹ 0 | ₹ 0 |
Avience Biomedicals SME IPO Dates
| Event | Date |
|---|---|
| Open Date | 18 Jun, 2026 |
| Close Date | 22 Jun, 2026 |
| Allotment Date | 23 Jun, 2026 |
| Refund Date | 24 Jun, 2026 |
| Credit to Demat | 24 Jun, 2026 |
| Listing Date | 25 Jun, 2026 |
Avience Biomedicals SME IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹208 |
| GMP-Based Estimate (Pre-Listing) | ₹353 (+69.7%) |
| Actual Listing Price | ₹395.20 (+90%) |
| Listing Gain / Loss | +₹187.2 per share |
| Listing Date | 25 Jun, 2026 |
Is Avience Biomedicals SME IPO GMP Reliable?
Grey market premium for Avience Biomedicals SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Avience Biomedicals SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Avience Biomedicals SME IPO IPO Kostak Rate Explained
The Kostak rate for Avience Biomedicals SME IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Avience Biomedicals SME IPO
The company is engaged in the manufacturing and distribution of molecular diagnostic kits, reagents and related healthcare products used by hospitals, laboratories and diagnostic centres. Its business model is based on developing and supplying testing solutions that support disease detection and clinical diagnostics. With increasing demand for advanced healthcare testing infrastructure, the company aims to expand its product portfolio and market reach across India.
Strengths & Risks
Strengths
- ✓ Operates in the fast-growing healthcare and molecular diagnostics sector.
- ✓ Focused product portfolio catering to hospitals and diagnostic laboratories.
- ✓ Rising demand for diagnostic testing supports long-term growth prospects.
- ✓ Experienced promoter group with healthcare industry exposure.
- ✓ Asset-backed manufacturing and distribution capabilities enhance scalability.
Risks
- ⚠ Business performance depends on regulatory approvals and healthcare compliance requirements.
- ⚠ Intense competition from established diagnostic and biomedical companies may affect growth.
- ⚠ Rapid technological changes could require continuous investment in product development.
- ⚠ Dependence on healthcare spending and diagnostic testing demand may impact revenues.
- ⚠ Relatively limited operating history compared to larger industry peers.
Frequently Asked Questions about Avience Biomedicals SME IPO
What is the GMP of Avience Biomedicals SME IPO?
The current Grey Market Premium (GMP) of Avience Biomedicals SME IPO is ₹ 145.
What is the Kostak Price of Avience Biomedicals SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Avience Biomedicals SME IPO is currently not available.
What is the Subject to Sauda Price of Avience Biomedicals SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What was the actual listing price of Avience Biomedicals SME IPO?
Avience Biomedicals SME IPO listed on June 25, 2026 at ₹395.20, against the issue price of ₹208 — a gain of +90%.
How did the GMP of Avience Biomedicals SME IPO trend before listing?
The GMP of Avience Biomedicals SME IPO was rising in its final days before listing. The GMP peaked at ₹145 on 25 June 2026. View the day-wise table above for the complete GMP history.
Explore Avience Biomedicals SME IPO Further
For a complete picture before making your investment decision, explore these resources:
Discussion 0
No comments yet
Be the first to share your thoughts!